COVID ‐19 State of Emergency and Biological Therapy Persistence for Ulcerative Colitis: An Interrupted Time Series Study Using a Nationwide Claims Database
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70377 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Mitsuhiro Mori und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, COVID-19, Drug Monitoring. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Purpose
To evaluate changes in biological therapy persistence for ulcerative colitis during Japan's first COVID‐19 state of emergency.
Methods
Using a nationwide health insurance claims database, we identified patients with ulcerative colitis who received biological maintenance therapy between January 2014 and December 2022. Interrupted time series analysis was used to evaluate immediate level changes and post‐intervention changes in trends in treatment non‐persistence after the state of emergency. Kaplan–Meier analysis compared time to non‐persistence between patients initiating biological therapy in the pre‐ and post‐intervention periods using log‐rank tests.
Results
Among 1197 eligible patients (67.1% male; median age, 40.0 years [interquartile range, 29.0–50.0 years]), 384 received infliximab; 375, adalimumab; 286, vedolizumab; and 152, golimumab. Interrupted time series analysis showed no clear evidence of an immediate level change in treatment non‐persistence after intervention (level change, 0.38; p = 0.822) or a post‐intervention change in trend (change in trend, −0.33; p = 0.167). Kaplan–Meier analysis showed no significant difference in time to non‐persistence between pre‐ and post‐intervention initiators.
Conclusions
Biological therapy persistence for ulcerative colitis was largely maintained during the COVID‐19 pandemic in Japan. These findings suggest that the pandemic was not associated with a marked change in treatment persistence in this setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
- Department of Digital Health and Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
- Department of Gastroenterology and Hepatology, Kumamoto University Hospital, Kumamoto, Japan.
- Department of Clinical Medicine, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
ORCID-Profile: Satomi Yoshida, Koji Kawakami
Zitieren
APA
Mori, M., Nakao, Y. M., Honda, M., Yoshida, S., & Kawakami, K. (2026). COVID ‐19 State of Emergency and Biological Therapy Persistence for Ulcerative Colitis: An Interrupted Time Series Study Using a Nationwide Claims Database. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70377
Vancouver
Mori M, Nakao YM, Honda M, Yoshida S, Kawakami K. COVID ‐19 State of Emergency and Biological Therapy Persistence for Ulcerative Colitis: An Interrupted Time Series Study Using a Nationwide Claims Database. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70377
BibTeX
@article{Mori2026,
author = {Mori, Mitsuhiro and Nakao, Yoko M and Honda, Munenori and Yoshida, Satomi and Kawakami, Koji},
title = {COVID ‐19 State of Emergency and Biological Therapy Persistence for Ulcerative Colitis: An Interrupted Time Series Study Using a Nationwide Claims Database},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70377}
}
EUVIMED